Abstract
Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR-encephalitis) was first described as an immune-mediated disorder of behavior and cognitive functions in patients with ovarian teratoma. Subsequently, it was recognized as a separate type of autoimmune encephalitis with a characteristic clinical picture and the possibility of development in the absence of data on tumor formations. The course can have both monophase and recurrent variants with periods of improvement or stabilization of the condition and subsequent progression of the disease. The article presents a clinical observation of a patient with a relapse of the disease 2 years later. The diagnosis of anti-NMDAR-encephalitis was established based on the presence of antibodies to NMDA receptor epitopes in the patient's cerebrospinal fluid, both at the onset of the disease and during the relapse. According to foreign literature, the incidence of recurrent anti-NMDAR-encephalitis varies from 12% to 24%, depending on the study, which requires additional monitoring of patients with this diagnosis.

This publication has 31 references indexed in Scilit: